Cynakalcet (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cynakalcet" in Polish language version.

refsWebsite

Global rank Polish rank

17nih.gov

4^th place

7^th place

12doi.org

2^nd place

6^th place

3endojournals.org

low place

4,234^th place

2oxfordjournals.org

1,389^th place

2,042^nd place

2aspetjournals.org

6,663^rd place

7,639^th place

1drugbank.ca

4,294^th place

205^th place

1asnjournals.org

low place

1wiley.com

222^nd place

228^th place

1mayoclinicproceedings.com

low place

1nejm.org

2,374^th place

2,071^st place

asnjournals.org

jasn.asnjournals.org

Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., Barri Y.M., Cohen R.M., Coburn J.W. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.. „Journal of the American Society of Nephrology : JASN”. 4 (13), s. 1017–24, kwiecień 2002. PMID: 11912261.

aspetjournals.org

jpet.aspetjournals.org

Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.. „The Journal of pharmacology and experimental therapeutics”. 2 (308), s. 627–35, luty 2004. DOI: 10.1124/jpet.103.057273. PMID: 14593085.

dmd.aspetjournals.org

Kumar G.N., Sproul C., Poppe L., Turner S., Gohdes M., Ghoborah H., Padhi D., Roskos L. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.. „Drug metabolism and disposition: the biological fate of chemicals”. 12 (32), s. 1491–500, grudzień 2004. DOI: 10.1124/dmd.104.000604. PMID: 15328250.

doi.org

Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.. „Clinical therapeutics”. 11 (27), s. 1725–51, listopad 2005. DOI: 10.1016/j.clinthera.2005.11.015. PMID: 16368445.
Giotta N., Marino A. Calcimimetics, calcium set point and calcium balance.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 12 (23), s. 4083–4, grudzień 2008. DOI: 10.1093/ndt/gfn440. PMID: 18728157.
Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.. „The Journal of pharmacology and experimental therapeutics”. 2 (308), s. 627–35, luty 2004. DOI: 10.1124/jpet.103.057273. PMID: 14593085.
Serra A.L., Braun S.C., Starke A., Savoca R., Hersberger M., Russmann S., Corti N., Wüthrich R.P. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.. „American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons”. 4 (8), s. 803–10, kwiecień 2008. DOI: 10.1111/j.1600-6143.2007.02136.x. PMID: 18318784.
Kumar G.N., Sproul C., Poppe L., Turner S., Gohdes M., Ghoborah H., Padhi D., Roskos L. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.. „Drug metabolism and disposition: the biological fate of chemicals”. 12 (32), s. 1491–500, grudzień 2004. DOI: 10.1124/dmd.104.000604. PMID: 15328250.
Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 2 (22), s. 637–40, luty 2007. DOI: 10.1093/ndt/gfl547. PMID: 17095580.
Lien YH., Silva AL., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 6 (20), s. 1232–7, czerwiec 2005. DOI: 10.1093/ndt/gfh829. PMID: 15840675.
Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.. „The Journal of clinical endocrinology and metabolism”. 1 (90), s. 135–41, styczeń 2005. DOI: 10.1210/jc.2004-0842. PMID: 15522938.
Silverberg S.J., Rubin M.R., Faiman C., Peacock M., Shoback D.M., Smallridge R.C., Schwanauer L.E., Olson K.A., Klassen P., Bilezikian J.P. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.. „The Journal of clinical endocrinology and metabolism”. 10 (92), s. 3803–8, październik 2007. DOI: 10.1210/jc.2007-0585. PMID: 17666472.
The EVOLVE Trial Investigators. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. „N Engl J Med”. 367, s. 2482–94, 2012-12-27. DOI: 10.1056/NEJMoa1205624. [dostęp 2015-10-03]. (ang.).
Tilling L., Colin Forfar J. Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.. „Clinical therapeutics”. 2 (29), s. 352–6, luty 2007. DOI: 10.1016/j.clinthera.2007.02.002. PMID: 17472827.
Harris R.Z., Salfi M., Posvar E., Hoelscher D., Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.. „European journal of clinical pharmacology”. 2 (63), s. 159–63, luty 2007. DOI: 10.1007/s00228-006-0129-8. PMID: 16680561.

drugbank.ca

Cinacalcet, [w:] DrugBank [online], University of Alberta, DB01012 (ang.).

endojournals.org

jcem.endojournals.org

Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.. „The Journal of clinical endocrinology and metabolism”. 1 (90), s. 135–41, styczeń 2005. DOI: 10.1210/jc.2004-0842. PMID: 15522938.
Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.. „The Journal of clinical endocrinology and metabolism”. 12 (88), s. 5644–9, grudzień 2003. PMID: 14671147.
Silverberg S.J., Rubin M.R., Faiman C., Peacock M., Shoback D.M., Smallridge R.C., Schwanauer L.E., Olson K.A., Klassen P., Bilezikian J.P. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.. „The Journal of clinical endocrinology and metabolism”. 10 (92), s. 3803–8, październik 2007. DOI: 10.1210/jc.2007-0585. PMID: 17666472.

mayoclinicproceedings.com

Farford B., Presutti RJ., Moraghan TJ. Nonsurgical management of primary hyperparathyroidism.. „Mayo Clinic proceedings. Mayo Clinic”. 3 (82), s. 351–5, marzec 2007. PMID: 17352371.

nejm.org

The EVOLVE Trial Investigators. Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. „N Engl J Med”. 367, s. 2482–94, 2012-12-27. DOI: 10.1056/NEJMoa1205624. [dostęp 2015-10-03]. (ang.).

nih.gov

ncbi.nlm.nih.gov

Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.. „Clinical therapeutics”. 11 (27), s. 1725–51, listopad 2005. DOI: 10.1016/j.clinthera.2005.11.015. PMID: 16368445.
Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., Barri Y.M., Cohen R.M., Coburn J.W. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.. „Journal of the American Society of Nephrology : JASN”. 4 (13), s. 1017–24, kwiecień 2002. PMID: 11912261.
Giotta N., Marino A. Calcimimetics, calcium set point and calcium balance.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 12 (23), s. 4083–4, grudzień 2008. DOI: 10.1093/ndt/gfn440. PMID: 18728157.
Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.. „The Journal of pharmacology and experimental therapeutics”. 2 (308), s. 627–35, luty 2004. DOI: 10.1124/jpet.103.057273. PMID: 14593085.
Serra A.L., Braun S.C., Starke A., Savoca R., Hersberger M., Russmann S., Corti N., Wüthrich R.P. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.. „American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons”. 4 (8), s. 803–10, kwiecień 2008. DOI: 10.1111/j.1600-6143.2007.02136.x. PMID: 18318784.
Schaefer R.M., Bover J., Dellanna F., Sanz D., Asensio C., Sánchez González M.C., Gross P., Zani V., Carter D., Jehle P.M. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study.. „Clinical nephrology”. 2 (70), s. 126–34, sierpień 2008. PMID: 18793528.
Kumar G.N., Sproul C., Poppe L., Turner S., Gohdes M., Ghoborah H., Padhi D., Roskos L. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models.. „Drug metabolism and disposition: the biological fate of chemicals”. 12 (32), s. 1491–500, grudzień 2004. DOI: 10.1124/dmd.104.000604. PMID: 15328250.
Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 2 (22), s. 637–40, luty 2007. DOI: 10.1093/ndt/gfl547. PMID: 17095580.
Lien YH., Silva AL., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 6 (20), s. 1232–7, czerwiec 2005. DOI: 10.1093/ndt/gfh829. PMID: 15840675.
Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.. „The Journal of clinical endocrinology and metabolism”. 1 (90), s. 135–41, styczeń 2005. DOI: 10.1210/jc.2004-0842. PMID: 15522938.
Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.. „The Journal of clinical endocrinology and metabolism”. 12 (88), s. 5644–9, grudzień 2003. PMID: 14671147.
Silverberg S.J., Rubin M.R., Faiman C., Peacock M., Shoback D.M., Smallridge R.C., Schwanauer L.E., Olson K.A., Klassen P., Bilezikian J.P. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.. „The Journal of clinical endocrinology and metabolism”. 10 (92), s. 3803–8, październik 2007. DOI: 10.1210/jc.2007-0585. PMID: 17666472.
Farford B., Presutti RJ., Moraghan TJ. Nonsurgical management of primary hyperparathyroidism.. „Mayo Clinic proceedings. Mayo Clinic”. 3 (82), s. 351–5, marzec 2007. PMID: 17352371.
Tilling L., Colin Forfar J. Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy.. „Clinical therapeutics”. 2 (29), s. 352–6, luty 2007. DOI: 10.1016/j.clinthera.2007.02.002. PMID: 17472827.
Harris R.Z., Salfi M., Sullivan J.T., Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.. „Clinical pharmacokinetics”. 6 (46), s. 495–501, 2007. PMID: 17518508.
Harris R.Z., Salfi M., Posvar E., Hoelscher D., Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.. „European journal of clinical pharmacology”. 2 (63), s. 159–63, luty 2007. DOI: 10.1007/s00228-006-0129-8. PMID: 16680561.

dailymed.nlm.nih.gov

Informacje FDA o leku. [dostęp 2009-04-15]. (ang.).

oxfordjournals.org

ndt.oxfordjournals.org

Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 2 (22), s. 637–40, luty 2007. DOI: 10.1093/ndt/gfl547. PMID: 17095580.
Lien YH., Silva AL., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.. „Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association”. 6 (20), s. 1232–7, czerwiec 2005. DOI: 10.1093/ndt/gfh829. PMID: 15840675.

wiley.com

www3.interscience.wiley.com

Serra A.L., Braun S.C., Starke A., Savoca R., Hersberger M., Russmann S., Corti N., Wüthrich R.P. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.. „American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons”. 4 (8), s. 803–10, kwiecień 2008. DOI: 10.1111/j.1600-6143.2007.02136.x. PMID: 18318784.